⌕
Denali Therapeutics · DNLI · Nasdaq
Tenet 54 · Mixed
Compare
$18.08−3.52%At closeTenet 54 · Mixed
$18.08−0.66 (−3.52%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Denali Therapeutics (DNLI) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~160.6%/yr (FY21→FY23), net margin −43.9%. Worth your attention in FY25: Share count (+42.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼21.2%
−512.5
FY21→FY25CAGR —
Free cash flow ($M)▼16.1%
−422.1
FY21→FY25CAGR —
Diluted EPS▼15.6%
−2.97
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+42.1%

121.5mn → 172.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$9.5M

−40.3% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−418.8R&D−136.6SG&A−555.3Op income42.8Tax & other−512.5Net income

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
21,382.00.00.0330,531.0108,463.048,661.0——
Cost of revenue
285.00.00.00.00.00.0——
Gross profit
21,097.00.00.0330,531.0108,463.048,661.0——
Research & development
404,872.0418,778.0396,440.0423,876.0358,732.0265,353.0▲5.6%+12.1%
Selling, general & admin
146,739.0136,564.0105,438.0103,354.090,475.079,059.0▲29.5%+14.6%
Total operating expenses
553,111.0555,342.0487,341.0527,230.0449,207.0344,412.0▲14.0%+12.7%
Operating incomefeeds ROC rank
−532,014.0−555,342.0−487,341.0−196,699.0−340,744.0−295,751.0▼14.0%—
Other income, net
217,693.042,904.064,636.051,505.014,774.00.0——
Pretax income
−314,321.0−512,438.0−422,705.0−145,194.0−325,970.0−295,751.0▼21.2%—
Income tax
—102.068.030.021.0−575.0▲50.0%+69.4% (22→25)
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−314,423.0−512,540.0−422,773.0−145,224.0−325,991.0−290,581.0▼21.2%—
Per share
Diluted EPSbuyback-sensitive
−1.73−2.97−2.57−1.06−2.60−2.39▼15.6%—
Diluted shares (mn)
192.08172.65164.47137.37125.53121.52▲5.0%+9.2%
Margins
Gross margin
98.7%——100.0%100.0%100.0%——
Operating margin
−2488.1%——−59.5%−314.2%−607.8%——
Net margin
−1470.5%——−43.9%−300.6%−597.2%——
† TTM = trailing four quarters through 2026-09-30.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.